AstraZeneca PLC
LSE:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
LSE:AZN
Watchlist
Price: 13 760 GBX 1.34%
Market Cap: 213.4B GBX

AstraZeneca PLC
Short-Term Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

AstraZeneca PLC
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
AstraZeneca PLC
LSE:AZN
Short-Term Debt
$1.7B
CAGR 3-Years
32%
CAGR 5-Years
7%
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Short-Term Debt
ÂŁ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Verona Pharma PLC
NASDAQ:VRNA
Short-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Short-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Short-Term Debt
$21m
CAGR 3-Years
-35%
CAGR 5-Years
-28%
CAGR 10-Years
-16%
Allergy Therapeutics PLC
LSE:AGY
Short-Term Debt
ÂŁ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

AstraZeneca PLC
Glance View

AstraZeneca PLC stands as a formidable entity in the global pharmaceutical landscape, adeptly navigating the intricate dance of innovation and commerce. Emerging from a merger between Sweden's Astra AB and the UK's Zeneca Group in 1999, the company has carved a niche through its relentless pursuit of cutting-edge medical solutions. Central to its operations is a sophisticated ecosystem of research and development, where thousands of scientists tirelessly explore the expansive frontier of biotechnology. The lifeblood of AstraZeneca's growth is its robust pipeline, where potential life-saving medicines traverse an arduous journey from laboratory benches to clinical trials, and eventually, regulatory approval. This rigorous process underscores its commitment to addressing complex diseases in areas such as oncology, cardiovascular, and respiratory health – domains marked by high unmet medical needs and significant market demand. The commercial prowess of AstraZeneca is equally vital to its success narrative. With a global reach spanning over 100 countries, the company leverages its advanced production facilities and strategic partnerships to deliver its pharmaceutical breakthroughs to those in need. Revenue generation is predominantly through the sale of prescription drugs, with blockbuster medications serving as pivotal financial pillars. These products, once approved, are strategically marketed to healthcare providers, ensuring they gain traction in various markets. AstraZeneca's approach is finely tuned to balance the scale of mass production with the nuance of catering to specific regional demands, maintaining a competitive edge in a crowded pharmaceutical landscape. Through these intricacies of innovation, production, and strategic market positioning, AstraZeneca not only generates substantial revenues but also reinforces its mission to improve patient health outcomes worldwide.

AZN Intrinsic Value
15 417.7 GBX
Undervaluation 11%
Intrinsic Value
Price

See Also

What is AstraZeneca PLC's Short-Term Debt?
Short-Term Debt
1.7B USD

Based on the financial report for Sep 30, 2025, AstraZeneca PLC's Short-Term Debt amounts to 1.7B USD.

What is AstraZeneca PLC's Short-Term Debt growth rate?
Short-Term Debt CAGR 5Y
7%

Over the last year, the Short-Term Debt growth was 38%. The average annual Short-Term Debt growth rates for AstraZeneca PLC have been 32% over the past three years , 7% over the past five years .

Back to Top